Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe
Shilpa Medicare has partnered with Orion Corporation to develop and supply a nivolumab biosimilar for the European market. This agreement aims to increase patient access to cancer immunotherapy by providing a more affordable alternative to the original drug.
Why it matters
Expands access to critical oncology treatments and highlights the role of biosimilars in reducing healthcare costs globally.
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe.
The article provides a factual account of a corporate partnership and its intended market impact.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in